Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: Tomato who wrote (338)	10/15/2000 4:26:20 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

1. Does the above mean that in addition to the $1.90 or so per share cash that they have liabilities of over $50 mil? 2. I thought the interest in Axiom was liability-free stock interest-- but it sounds instead like they may be liable for Axiom's debts. ???? 3. When Richard Harmon says he's KDUS not for the cash but for the royalties, is he talking about the $100k per year licensing and other possible licensing fees or possible royalties from its core yeast technology or what? No, an accumulated deficit is, if anything, a positive. No, there is no obligation for Axiom liabilities. "What"...... largely potential royalty flow from the OSIP-proprietary and OSIP-Solvay projects. But, yes, licensing and royalty income from the core yeast technology as well.